Overview
Compare with Anbio Biotechnology, BIOMERICA INC or Insight Molecular Diagnostics Inc., or pick any stock.
- TickerAWHL on OTC2
- IndustryIn Vitro & In Vivo Diagnostic Substances2
- HeadquartersAustin, United States2
- Incorporated inDE3
- Business address12117 Bee Caves Road Building Three, Suite 100, Austin, Tx 787383
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation2
- LEI54930045CGQ3XUO9T5332
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 32332042
See how the biggest companies compare on our leaderboards
Aspira Women’s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases, starting with ovarian cancer.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
64.2%Gross margin5
-85.9%Operating margin5
-138.7%Net margin5
0.4%Revenue growth, 20255
-$7.0MFree cash flow5
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue36¢$3.3M
- Research and development31¢$2.9M
- Other costs33¢$3.0M
Out of $9.2M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenue | $9.2M | $9.2M |
| Total cost of revenue | $3.3M | $3.7M |
| Gross profit | $5.9M | $5.5M |
| Research and development | $2.9M | $3.3M |
| Sales and marketing | $3.0M | $8.1M |
| General and administrative | $8.0M | $10.3M |
| Total operating expenses | $13.8M | $21.8M |
| Loss from operations | -$7.9M | -$16.3M |
| Change in fair value of warrant liabilities | -$5.6M | $1.3M |
| Change in fair value of convertible notes | $170.0K | |
| Loss upon issuance of convertible notes carried at fair value | -$1.2M | |
| Interest expense, net | -$41.0K | -$33.0K |
| Other income (expense), net | $1.8M | $1.9M |
| Total other (expense) income, net | -$4.9M | $3.2M |
| Net loss | -$12.8M | -$13.1M |
| Net loss per share - basic (in dollars per share) | -$0.37 | -$0.93 |
| Net loss per share - diluted (in dollars per share) | -$0.37 | -$0.93 |
| Weighted average common shares used to compute basic net loss per common share (in shares) | 34.1M shares | 14.1M shares |
| Weighted average common shares used to compute diluted net loss per common share (in shares) | 34.1M shares | 14.1M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 2 fiscal years (annual) or 2 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash and cash equivalents | $1.8M | $1.8M |
| Accounts receivable, net of reserves of $44 | $1.2M | $990.0K |
| Prepaid expenses and other current assets | $845.0K | $1.1M |
| Inventories | $256.0K | $326.0K |
| Total current assets | $4.1M | $4.2M |
| Property and equipment, net | $47.0K | $69.0K |
| Intangible assets, net | $310.0K | |
| Right-of-use assets | $980.0K | $1.2M |
| Other assets | $56.0K | $45.0K |
| Total assets | $5.5M | $5.5M |
| Accounts payable | $1.2M | $2.2M |
| Accrued liabilities | $1.3M | $2.4M |
| Current portion of long-term debt | $236.0K | $229.0K |
| Short-term debt | $493.0K | $614.0K |
| Current maturities of lease liabilities | $202.0K | $7.0K |
| Total current liabilities | $3.5M | $5.5M |
| Long-term debt | $1.0M | $1.3M |
| Non-current maturities of lease liabilities | $1.0M | $1.2M |
| Warrant liabilities | $6.9M | $60.0K |
| Total liabilities | $12.4M | $8.1M |
| Common stock, par value $0.001 per share, 200,000,000 shares authorized at December 31, 2025 and December 31, 2024; 43,480,411 and 17,407,120 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $43.0K | $17.0K |
| Additional paid-in capital | $537.2M | $528.8M |
| Accumulated deficit | -$544.2M | -$531.4M |
| Total stockholders' deficit | -$6.9M | -$2.6M |
| Total liabilities and stockholders' deficit | $5.5M | $5.5M |
| Accounts receivable, allowance | $44.0K | $44.0K |
| Preferred stock, par value | $0.00 | $0.00 |
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares |
| Preferred Stock, shares issued | 0 shares | 0 shares |
| Preferred Stock, shares outstanding | 0 shares | 0 shares |
| Common stock, par value | $0.00 | $0.00 |
| Common stock, shares authorized | 200.0M shares | 200.0M shares |
| Common stock, shares issued | 43.5M shares | 17.4M shares |
| Common stock, shares outstanding | 43.5M shares | 17.4M shares |
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash and cash equivalents | $1.8M | $1.8M |
| Accounts receivable, net of reserves of $44 | $1.2M | $990.0K |
| Prepaid expenses and other current assets | $845.0K | $1.1M |
| Inventories | $256.0K | $326.0K |
| Total current assets | $4.1M | $4.2M |
| Property and equipment, net | $47.0K | $69.0K |
| Intangible assets, net | $310.0K | |
| Right-of-use assets | $980.0K | $1.2M |
| Other assets | $56.0K | $45.0K |
| Total assets | $5.5M | $5.5M |
| Accounts payable | $1.2M | $2.2M |
| Accrued liabilities | $1.3M | $2.4M |
| Current portion of long-term debt | $236.0K | $229.0K |
| Short-term debt | $493.0K | $614.0K |
| Current maturities of lease liabilities | $202.0K | $7.0K |
| Total current liabilities | $3.5M | $5.5M |
| Long-term debt | $1.0M | $1.3M |
| Non-current maturities of lease liabilities | $1.0M | $1.2M |
| Warrant liabilities | $6.9M | $60.0K |
| Total liabilities | $12.4M | $8.1M |
| Common stock, par value $0.001 per share, 200,000,000 shares authorized at December 31, 2025 and December 31, 2024; 43,480,411 and 17,407,120 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $43.0K | $17.0K |
| Additional paid-in capital | $537.2M | $528.8M |
| Accumulated deficit | -$544.2M | -$531.4M |
| Total stockholders' deficit | -$6.9M | -$2.6M |
| Total liabilities and stockholders' deficit | $5.5M | $5.5M |
| Accounts receivable, allowance | $44.0K | $44.0K |
| Preferred stock, par value | $0.00 | $0.00 |
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares |
| Preferred Stock, shares issued | 0 shares | 0 shares |
| Preferred Stock, shares outstanding | 0 shares | 0 shares |
| Common stock, par value | $0.00 | $0.00 |
| Common stock, shares authorized | 200.0M shares | 200.0M shares |
| Common stock, shares issued | 43.5M shares | 17.4M shares |
| Common stock, shares outstanding | 43.5M shares | 17.4M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Income (Loss) | -$12.8M | -$13.1M |
| Non-cash lease expense | $169.0K | $3.0K |
| Depreciation and amortization | $112.0K | $92.0K |
| Stock-based compensation expense | $531.0K | $1.5M |
| Change in fair value of warrant liabilities | $5.6M | -$1.3M |
| Change in fair value of March 2025 Convertible Notes | -$170.0K | |
| Loss upon issuance of March 2025 Convertible Notes carried at fair value | $1.2M | |
| Loss on impairment and disposal of property and equipment | $1.0K | $41.0K |
| Financing expense for entering into 2025 Lincoln Park Equity Line of Credit | $412.0K | |
| Accounts receivable | -$217.0K | $469.0K |
| Prepaid expenses and other assets | $242.0K | -$115.0K |
| Inventories | $68.0K | -$99.0K |
| Accounts payable | -$936.0K | $912.0K |
| Accrued liabilities | -$1.1M | -$418.0K |
| Other liabilities | -$118.0K | -$52.0K |
| Net cash used in operating activities | -$7.0M | -$12.1M |
| Purchase of property and equipment | -$16.0K | -$37.0K |
| Purchase of intangible assets | -$385.0K | |
| Net cash used in investing activities | -$401.0K | -$37.0K |
| Principal repayment of DECD loan | -$233.0K | -$93.0K |
| Proceeds from issuance of common stock from exercise of warrants | $112.0K | |
| Proceeds from March 2025 Convertible Notes | $1.4M | |
| Net cash provided by financing activities | $7.4M | $11.1M |
| Net decrease in cash and cash equivalents | -$14.0K | -$1.1M |
| Cash paid for interest | $34.0K | $49.0K |
| Increase in right-of-use assets | $895.0K | |
| Fair value of warrants issued in conjunction with Warrant Inducement Agreement | $1.3M | |
| Fair value of warrants issued upon conversion of Convertible Notes | $1.5M | |
| Fair value of common stock issued upon conversion of Convertible Notes | $916.0K |
No quarter-by-quarter statement was filed.
Corporate structure
Aspira Women's Health Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Aspira Women's Health Inc.
- Jack W. Schuler Filed SCHEDULE 13D/A on Aspira Women's Health Inc., latest Jun 11, 2026 (7 filings since Aug 29, 2022)
- ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Aspira Women's Health Inc., latest Feb 14, 2025 (2 filings since Nov 14, 2024)
- Eric Adam Schultz Filed SC 13G/A on Aspira Women's Health Inc., latest Apr 8, 2024 (2 filings since Dec 26, 2023)
- SEAMARK CAPITAL LP Filed SC 13G/A on Aspira Women's Health Inc., latest Feb 15, 2023 (2 filings since Feb 16, 2022)
- Robert H. Drysdale Filed SC 13G on Aspira Women's Health Inc., latest Feb 14, 2022
- Tanya Schuler Sharman Filed SC 13D/A on Aspira Women's Health Inc., latest Jan 13, 2022
- Henri George Schuler Filed SC 13D/A on Aspira Women's Health Inc., latest Dec 30, 2021
- Tino Hans Schuler Filed SC 13D/A on Aspira Women's Health Inc., latest Dec 30, 2021
- Larry N. Feinberg Filed SC 13D/A on Aspira Women's Health Inc., latest Nov 24, 2021
- Aspira Women's Health Inc. Austin, Texas, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Aspira Women's Health Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $1.4M5 Dec 31, 2025 | $1.5M5 Dec 31, 2024 | −7.4% |
| Accumulated depreciation | $1.3M5 Dec 31, 2025 | $1.4M5 Dec 31, 2024 | −6.2% |
| Property and equipment, net | $47.0K5 Dec 31, 2025 | $69.0K5 Dec 31, 2024 | −31.9% |
| Operating-lease assets (leased space) | $980.0K5 Dec 31, 2025 | $1.2M5 Dec 31, 2024 | −17.9% |
Investments
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Finite-lived intangibles, gross | $385.0K5 Dec 31, 2025 | ||
| Accumulated amortization | $75.0K5 Dec 31, 2025 | ||
| Finite-lived intangibles, net | $310.0K5 Dec 31, 2025 |
Inventory
Properties, in its own words
The following chart indicates the facilities that we lease, the location and size of each facility and its designated use. We believe that these facilities are suitable and adequate for our current needs.
Location · Approximate Square Feet · Primary Functions · Lease Expiration Date
The rest of Item 2
Austin, Texas · 8,203 sq. ft. · Aspira Labs facility, research and development, clinical and regulatory and administrative offices · August 31, 2031
Shelton, Connecticut · 4,614 sq. ft. · Administrative offices · September 30, 2028
Item 2 of the 10-K filed Apr 1, 2026.4
Leadership
Who has led Aspira Women's Health Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerSandra Milligan Jan 8, 2025 to Mar 19, 202513
- Chief executive officerMichael William Buhle Mar 19, 2025 to now14
- Chief executive officerNicole Sandford Mar 1, 2022 to Oct 28, 202415
- Chief executive officerValerie Barber Palmieri Mar 21, 2016 to Mar 23, 202116
- Chief executive officerJames T. Lafrance Apr 24, 2014 to Jul 28, 201417
- Chief executive officerThomas H. McLain Mar 20, 2013 to Mar 31, 201418
- Chief executive officerBruce A. Huebner Nov 28, 2012 to Nov 28, 201219
- Chief executive officerGail S. Page Jun 9, 2006 to Mar 26, 201220
- ChairValerie Barber Palmieri May 18, 2022 to May 18, 202221
- PresidentSandra Milligan Apr 4, 2024 to Jan 8, 202522
- PresidentNicole Sandford Mar 1, 2022 to Feb 20, 202415
- PresidentValerie Barber Palmieri Jan 5, 2015 to Mar 23, 202123
- PresidentJames T. Lafrance Apr 24, 2014 to Dec 23, 201417
- PresidentThomas H. McLain Mar 20, 2013 to Mar 31, 201418
- PresidentBruce A. Huebner Nov 28, 2012 to Nov 28, 201219
- PresidentGail S. Page Jun 9, 2006 to Nov 5, 200820
- Chief financial officerJohn Strahley Jul 15, 2026 to now24
- Chief financial officerBrian Hungerford Sep 4, 2025 to Jul 15, 202625
- Chief financial officerJohn A. Kallassy Aug 22, 2024 to Nov 14, 202426
- Chief financial officerMarlene McLennan Feb 8, 2023 to Feb 8, 202327
- Chief financial officerTorsten Hombeck Jun 29, 2023 to Jun 14, 202428
- Chief financial officerRobert Harry Beechey Dec 20, 2017 to Apr 4, 202229
- Chief financial officerSandra Gardiner May 21, 2010 to Mar 22, 201130
- Chief financial officerQun Zhou Nov 13, 2007 to Jul 22, 200831
- Chief financial officerDebra A. Young Nov 6, 2006 to Jul 24, 200732
- Chief operating officerRyan Thinh Phan Jul 12, 2022 to Jul 25, 202333
- Chief operating officerFred Ferrara Nov 3, 2016 to Apr 17, 201834
- Chief operating officerValerie Barber Palmieri Oct 27, 2014 to Nov 25, 201435
Board members and other officers (46)
- Chief Finacial OfficerJohn Strahley Jul 15, 2026 to now36
- SVP Sales & Cust ExperienceLaura Ann Miller Jan 20, 2015 to Feb 18, 201537
- Chief Information OfficerFred Ferrara Apr 2, 2015 to Mar 21, 201638
- VP Sales & Managed MarketsHolly B. Bauzon Sep 24, 2014 to Jul 8, 201539
- OfficerMarian E. Sacco Dec 18, 2013 to Mar 31, 201440
- Chief Accounting OfficerEric Schoen Oct 11, 2011 to Mar 27, 201741
- CSO, VP of R & DDonald G. Munroe Oct 12, 2011 to Mar 21, 201642
- VP, Finance & CAOJohn H. Tran Mar 23, 2010 to Mar 23, 201043
- VP Sales and MarketingWilliam B. Creech Mar 23, 2010 to Nov 22, 201344
- VP of Corporate StrategyAshish Kohli Oct 1, 2010 to Sep 15, 201145
- VP, Corp Business DevelopmentSimon C. Shorter Aug 22, 2008 to Aug 22, 200846
- VP-Chief Science OfficerEric T. Fung Jul 27, 2007 to Jun 9, 201147
- SeniorVP-Sales & MktgSteve Lundy Jul 27, 2007 to Jul 27, 200748
- Vice President, OperationsWilliam C. Sullivan Apr 21, 2006 to Jul 24, 200749
- EVP, Sales & MarketingJames P. Merryweather Jun 9, 2006 to Jun 9, 200650
- Board memberEllen Beausang Apr 1, 2025 to now51
- Board memberCynthia D. Hundorfean Apr 24, 2025 to now52
- Board memberJohn Phillip Ragard Jul 29, 2024 to now53
- Board memberEllen O'Connor Vos May 18, 2023 to now54
- Board memberJannie Prestridge Herchuk May 18, 2023 to now55
- Board memberStefanie L. Cavanaugh May 18, 2023 to now56
- Board memberWinfred Parnell Jun 5, 2023 to now57
- Board memberCeleste Rachelle Fralick Mar 1, 2022 to now58
- Board memberRobert D. Auerbach Jun 27, 2022 to Feb 13, 202359
- Board memberRuby Sharma Jun 27, 2022 to Feb 13, 202360
- Board memberNicole Sandford Mar 8, 2021 to Oct 28, 202461
- Board memberSandra Elaine Brooks Nov 19, 2020 to Mar 23, 202162
- Board memberNancy G. Cocozza Aug 21, 2018 to Mar 23, 202163
- Board memberValerie Barber Palmieri Mar 21, 2016 to Mar 23, 202116
- Board memberDavid Schreiber Dec 19, 2014 to Mar 23, 202164
- Board memberVeronica Gh Jordan Dec 19, 2014 to Dec 27, 202365
- Board memberRobert St Leger Goggin Apr 1, 2013 to Dec 23, 201466
- Board memberEric Varma Sep 18, 2013 to Mar 31, 201467
- Board memberJames T. Lafrance Dec 20, 2013 to Apr 4, 202268
- Board memberBruce A. Huebner May 20, 2011 to Nov 28, 201269
- Board memberCarl Severinghaus Apr 21, 2010 to Apr 17, 201870
- Board memberPeter S. Roddy Apr 22, 2010 to Apr 19, 201671
- Board memberWilliam C. Wallen Apr 23, 2010 to May 17, 201272
- Board memberJohn F. Hamilton Apr 11, 2008 to Dec 14, 201273
- Board memberKenneth J. Conway Apr 14, 2006 to Oct 30, 200874
- Board memberGail S. Page Jun 9, 2006 to Mar 26, 201220
- Board memberJames L. Rathmann Jun 9, 2006 to Oct 30, 200875
- Board memberJudy Bruner Jun 9, 2006 to Sep 18, 200776
- Board memberMichael J. Callaghan Jun 9, 2006 to Sep 18, 200777
- Board memberRajen Dalal Jun 9, 2006 to Oct 30, 200878
- General counselMinh Hoang Merchant Jul 5, 2022 to Feb 14, 202479
Named in SEC Form D filings
People the company listed in its private-offering notices.
- Interim Chief Executive OfficerJOHN FRASER named Jun 22, 202680
- VP of FinanceJAMES CRAWFORD named Mar 20, 202581
- Executive OfficerJody Berry named Feb 7, 202482
- DirectorJEFFREY COHEN named Sep 18, 2025 to Jun 22, 202680
- DirectorJane PINE WOOD named Sep 18, 2025 to Jun 22, 202680
- DirectorJACK FRASER named Sep 18, 202583
- DirectorLynn O'Connor Vos named Feb 7, 202482
Former names
Timeline
- Jul 15, 20268-K Entered a material agreement; New debt or obligation84
- Jul 7, 20268-K Executive or director change85
- Jun 22, 20268-K Executive or director change86
- Jun 17, 20268-K Shareholder vote87
- Jun 9, 20268-K Entered a material agreement; Unregistered sale of shares88
- May 26, 20268-K Entered a material agreement89
- Apr 30, 20268-K Executive or director change90
- Mar 25, 20268-K Entered a material agreement91
- Jan 30, 20268-K Entered a material agreement; New debt or obligation92
- Dec 31, 20258-K Regulation FD disclosure93
- Dec 23, 20258-K Entered a material agreement; Unregistered sale of shares94
- Dec 22, 20258-K Entered a material agreement95
- Mar 19, 2025New chief executive Michael William Buhle becomes CEO14
- Jan 8, 2025New chief executive Sandra Milligan becomes CEO13
- Mar 1, 2022New chief executive Nicole Sandford becomes CEO15
- May 23, 2020Founded Aspira Women's Health Inc. is founded2
- Mar 21, 2016New chief executive Valerie Barber Palmieri becomes CEO16
- Apr 24, 2014New chief executive James T. Lafrance becomes CEO17
- Mar 20, 2013New chief executive Thomas H. McLain becomes CEO18
- Nov 28, 2012New chief executive Bruce A. Huebner becomes CEO19
- Jun 9, 2006New chief executive Gail S. Page becomes CEO20
Calendar
When it reported results
- Nov 14, 2025Reported quarterly or annual results96
- Aug 13, 2025Reported quarterly or annual results97
- May 19, 2025Reported quarterly or annual results98
- Mar 27, 2025Reported quarterly or annual results99
- Nov 14, 2024Reported quarterly or annual results100
- Aug 12, 2024Reported quarterly or annual results101
- May 15, 2024Reported quarterly or annual results102
- Mar 28, 2024Reported quarterly or annual results103
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
411 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 111 major events, 176 insider forms, 18 large holders, 5 private raises, 80 other. The latest 20:
- Oct 2, 20264 EDGAR
- Aug 14, 202610-Q EDGAR
- Jul 17, 20264/A EDGAR
- Jul 15, 20264 EDGAR
- Jul 15, 20263 EDGAR
- Jul 15, 20268-K EDGAR
- Jul 7, 20268-K/A EDGAR
- Jun 22, 2026D EDGAR
- Jun 22, 20268-K EDGAR
- Jun 17, 20268-K EDGAR
- Jun 11, 2026SCHEDULE 13D/A EDGAR
- Jun 9, 20264 EDGAR
- Jun 9, 20268-K EDGAR
- May 29, 20264 EDGAR
- May 29, 20264/A EDGAR
- May 29, 20264/A EDGAR
- May 29, 2026DEFA14A EDGAR
- May 26, 20268-K EDGAR
- May 15, 202610-Q EDGAR
- Apr 30, 20268-K EDGAR
The 411 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
33 open-market trades by officers, directors and large owners since October 2021: 32 buys and 1 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | SCHULER JACK W10% owner | Buy | 222,222 | $0.45 | $100.0K | Form 4 |
| Sep 17, 2025 | Fraser John DDirector | Buy | 16,389 | $0.45 | $7.4K | Form 4 |
| Sep 17, 2025 | cohen Jeffrey kDirector | Buy | 55,556 | $0.45 | $25.0K | Form 4 |
| Sep 17, 2025 | SCHULER JACK W10% owner | Buy | 1,111,111 | $0.45 | $500.0K | Form 4 |
| Sep 17, 2025 | cohen Jeffrey kDirector | Buy | 55,556 | $0.45 | $25.0K | Form 4 |
| Sep 17, 2025 | Fraser John DDirector | Buy | 16,389 | $0.45 | $7.4K | Form 4 |
| Jul 9, 2024 | SCHULER JACK W10% owner | Buy | 6,536 | Form 4 | ||
| May 31, 2024 | Sandford NicoleChief Executive Officer | Buy | 9,493 | $2.42 | $23.0K | Form 4 |
| Jan 26, 2024 | Sandford NicoleChief Executive Officer | Buy | 2,400 | Form 4 | ||
| Jan 26, 2024 | SCHULER JACK W10% owner | Buy | 28,500 | Form 4 | ||
| Dec 6, 2023 | Merchant Minh HoangGeneral Counsel and Secretary | Sale | 980 | $3.37 | $3.3K | Form 4 |
| Dec 6, 2023 | Sandford NicoleChief Executive Officer | Buy | 5,000 | $3.36 | $16.8K | Form 4 |
| Sep 8, 2023 | Hombeck TorstenChief Financial Officer | Buy | 2,246 | $4.30 | $9.7K | Form 4 |
| Jul 24, 2023 | Hombeck TorstenChief Financial Officer | Buy | 754 | $3.98 | $3.0K | Form 4 |
| Jul 24, 2023 | Parnell WinfredDirector | Buy | 6,281 | $3.98 | $25.0K | Form 4 |
| Jul 24, 2023 | Herchuk Jannie PrestridgeDirector | Buy | 8,794 | $3.98 | $35.0K | Form 4 |
| Jul 24, 2023 | Phan Ryan ThinhCSO & COO | Buy | 628 | $3.98 | $2.5K | Form 4 |
| Jul 24, 2023 | Merchant Minh HoangGeneral Counsel and Secretary | Buy | 754 | $3.98 | $3.0K | Form 4 |
| Jul 24, 2023 | Fralick Celeste RachelleDirector | Buy | 754 | $3.98 | $3.0K | Form 4 |
| Jul 24, 2023 | Sandford NicoleChief Executive Officer | Buy | 12,563 | $3.98 | $50.0K | Form 4 |
All 33 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Jack W. SchulerSCHEDULE 13D/A, 7 filings Aug 29, 2022 to Jun 11, 2026104
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 2 filings Nov 14, 2024 to Feb 14, 2025105
- Eric Adam SchultzSC 13G/A, 2 filings Dec 26, 2023 to Apr 8, 2024106
- SEAMARK CAPITAL LPSC 13G/A, 2 filings Feb 16, 2022 to Feb 15, 2023107
- Robert H. DrysdaleSC 13G, 1 filing Feb 14, 2022108
- Tanya Schuler SharmanSC 13D/A, 1 filing Jan 13, 2022109
- Henri George SchulerSC 13D/A, 1 filing Dec 30, 2021110
- Tino Hans SchulerSC 13D/A, 1 filing Dec 30, 2021111
- Larry N. FeinbergSC 13D/A, 1 filing Nov 24, 2021112
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
Funding
Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.
- Private raises (Form D) $14.2M
Figures by year
| Year | Private raises (Form D) | Total |
|---|---|---|
| 2026 | $1.5M | $1.5M |
| 2025 | $4.3M | $4.3M |
| 2024 | $8.4M | $8.4M |
Private raises
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
- Jun 5, 2026Raised $1.5 million in a private offering of equity80 Form D: 19 investors so far Form D
- Sep 16, 2025Raised $3 million in a private offering of equity83 Form D: 19 investors so far Form D
- Mar 5, 2025Raised $1.4 million in a private offering of securities81 Form D: 27 investors so far Form D
- Jun 30, 2024Raised $1.9 million in a private offering of equity114 Form D: 21 investors so far Form D
- Jan 26, 2024Raised $6.5 million in a private offering of securities82 Form D: 7 investors so far Form D
SEC filer profile
How Aspira Women's Health Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARAspira Women's Health Inc.1
- CIK0000926617
- Employer ID (EIN)33-05951564
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)2835 In Vitro & In Vivo Diagnostic Substances1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address12117 Bee Caves Road Building Three, Suite 100, Austin, TX 787381
- Phone512-519-04001
- Shares outstanding46,633,744 as of Aug 12, 202612
- Public float$4.7M as of Jun 30, 20254
- AuditorBDO USA, P.C, Boston, Massachusetts PCAOB ID 243; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceMar 20, 20001
- Filings1,549 in all: 4 (461), 8-K (377), SC 13G/A (80), 10-Q (78), 3 (67), SC 13D/A (59), SC 13G (31), UPLOAD (31)1
All 57 form types
CORRESP (28), DEF 14A (27), 10-K (24), DEFA14A (23), EFFECT (20), 4/A (19), 424B5 (18), 424B3 (16), S-1/A (16), S-8 (16), 8-K/A (15), S-3 (13), DFAN14A (11), 10-K/A (8), D (8), PRE 14A (8), S-1 (8), S-8 POS (8), ARS (6), NT 10-Q (6), SC 13D (6), NT 10-K (5), PRRN14A (5), REGDEX (5), 10-Q/A (4), PRER14A (4), 3/A (3), CT ORDER (3), DEFR14A (3), POS AM (3), S-3/A (3), SCHEDULE 13D/A (3), 10-K405 (2), 8-A12G (2), PREN14A (2), 25-NSE (1), 424B1 (1), 424B4 (1), 5 (1), 8-A12B (1), CERTNAS (1), DEFM14A (1), DEFN14A (1), FWP (1), PREC14A (1), PREM14A (1), RW (1), S-1MEF (1), SCHEDULE 13G/A (1)
- Latest filingsAnnual report (10-K) Apr 1, 2026
Quarterly report (10-Q) Aug 14, 2026
Proxy statement (DEF 14A) Apr 24, 2026
Latest 8-K (8-K) Jul 15, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.001 per share | AWHL |
From the cover page of the 10-K filed Apr 1, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks Aspira Women's Health Inc. names in Item 1A of its 10-K filed Apr 1, 2026: 38 risks under these headings, as written.4
- RISKS RELATED TO OUR BUSINESS AND INDUSTRY
- If we are unable to increase the volume of OvaSuite sales, our business, results of operations and financial condition will be adversely affected.
- There is substantial doubt about our ability to continue as a going concern, and this may adversely affect our stock price and our ability to raise capital.
- We may need to sell additional shares of our common stock or other securities in the future to meet our capital requirements, which could cause significant dilution.
- We will need to raise additional capital in the future, and if we are unable to secure adequate funds on terms acceptable to us, we may be unable to execute our business plan.
- Failures by third-party payers to reimburse for our products and services or changes in reimbursement rates could materially and adversely affect our business, financial condition and results of operations. In addition, changes in medical society guidelines may also adversely affect payers and result in a material change in coverage, adversely affecting our business, financial condition and results of operations.
- Failure to continue coverage of Ova1 through Novitas, our Medicare Administrative Contractor for Ova1, could materially and adversely affect our business, financial condition and results of operation.
- Failure to expand commercial, Medicare or Medicaid coverage for our products could materially and adversely affect our business, financial condition and results of operations.
- We may not succeed in improving existing or developing additional diagnostic products, and, even if we do succeed in developing additional diagnostic products, the diagnostic products may never achieve significant commercial market acceptance.
- The diagnostics market is competitive, and we may not be able to compete successfully, which would adversely impact our ability to generate revenue.
- We are currently offering and developing multiple tests as LDTs and intend to develop and perform LDTs at Aspira Labs in the future. If FDA were to begin actively regulating our tests, we would incur substantial costs and delays associated with the effort to obtain premarket 510(k) clearance, de novo classification, or premarket approval and incur costs related to compliance with post-market controls.
- Certain of our diagnostic tests and associated software are subject to ongoing regulation by the FDA, and we may develop additional FDA-regulated diagnostic tests and software in the future. Any failure to comply with applicable FDA regulations for our current FDA regulated products, and any delay by or failure of the FDA to authorize future products we submit to the FDA may adversely affect our business, results of operations and financial condition.
The other 27 risks
- If we or our suppliers fail to comply with FDA requirements for production, marketing and post-market monitoring of our products, we may not be able to market our products and services and may be subject to stringent penalties, product restrictions or recall.
- If our suppliers fail to produce acceptable or sufficient stock, fail to supply stock due to supply shortages, make changes to the design or labeling of their biomarker kits or discontinue production of existing biomarker kits or instrument platforms, we may be unable to meet market demand for OvaSuite products.
- Changes in healthcare policy could increase our costs and adversely impact sales of and reimbursement for our tests, which would have an adverse effect on our business, financial condition and results of operations.
- We are subject to environmental laws and potential exposure to environmental liabilities.
- The operation of Aspira Labs requires us to comply with numerous laws and regulations, which is expensive and time-consuming and could adversely affect our business, financial condition and results of operations, and any failure to comply could result in exposure to substantial penalties and other harm to our business.
- Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
- If we are able to successfully reinstate the ARPA-H award and yet are unable to complete the required milestones under our federal award milestone-based funding agreement, our business, results of operations and financial condition would be adversely affected.
- Failure to renew our Quest Diagnostics agreement could impact our business
- Our current agreement with Quest Diagnostics expired as of December 31, 2025. If we fail to renew the agreement on acceptable terms, we could experience a disruption in logistics as well as a loss of revenue.
- RISKS RELATED TO INTELLECTUAL PROPERTY AND PRODUCT LIABILITY
- If we fail to maintain our rights to utilize intellectual property directed to diagnostic biomarkers, we may not be able to offer diagnostic tests using those biomarkers.
- If a third party infringes on our proprietary rights, we may lose any competitive advantage we have as a result of diversion of our time, enforcement costs and the loss of the exclusivity of our proprietary rights.
- If others successfully assert their proprietary rights against us, we may be precluded from making and selling our products or we may be required to obtain licenses to use their technology.
- Our diagnostic efforts may cause us to have significant product liability exposure.
- Certain of our patent registrations will expire, which may cause us to have significant competition.
- OPERATIONAL RISKS
- Because our business is highly dependent on key executives and employees, our inability to recruit and retain these people could hinder our business plans.
- Business interruptions could limit our ability to operate our business.
- We selectively explore acquisition opportunities and strategic alliances relating to other businesses, products or technologies. We may not be successful in integrating other businesses, products or technologies with our business. Any such transaction also may not produce the results we anticipate, which could adversely affect our business, financial condition and results of operations.
- Future litigation by or against us could be costly and time-consuming to prosecute or defend.
- RISKS RELATED TO OWNING OUR STOCK
- There is a limited market for our Common Stock.
- If we fail to maintain compliance with the OTC QX minimum listing requirements, our common stock will be subject to removal to the OTC QB market. Our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if our common stock is downgraded.
- The liquidity and trading volume of our common stock may be low, and our ownership is concentrated, which could adversely impact the trading price of our common stock and our stockholders’ ability to obtain liquidity.
- Our stock price has been, and may continue to be, highly volatile.
- Anti-takeover provisions in our charter, bylaws, other agreements and under Delaware law could make a third-party acquisition of the Company difficult.
- If we raise additional capital in the future, your ownership in us could be diluted.
- Sales of a substantial number of our shares of common stock in the public market could cause our stock price to fall.
- Because we do not currently intend to declare cash dividends on our shares of common stock in the foreseeable future, stockholders must rely on appreciation of the value of our common stock for any return on their investment.
- The exercise of our outstanding options and warrants will dilute stockholders and could decrease our stock price.
Legal proceedings
From time to time, we are involved in legal proceedings and regulatory proceedings arising out of our operations. We establish reserves for specific liabilities in connection with legal actions that we deem to be probable and estimable. As of the date of the filing of this Form 10-K, we are not a party to any proceeding, the adverse outcome of which would have a material adverse effect on our financial position or results of operations.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21SEC EDGARValerie Barber Palmieri, Chair
- 22SEC EDGARSandra Milligan, President
- 23SEC EDGARValerie Barber Palmieri, President
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31SEC EDGARQun Zhou, Chief financial officer
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40SEC EDGARMarian E. Sacco, Officer
- 41
- 42SEC EDGARDonald G. Munroe, CSO, VP of R & D
- 43SEC EDGARJohn H. Tran, VP, Finance & CAO
- 44
- 45
- 46
- 47
- 48SEC EDGARSteve Lundy, SeniorVP-Sales & Mktg
- 49
- 50
- 51SEC EDGAREllen Beausang, Board member
- 52SEC EDGARCynthia D. Hundorfean, Board member
- 53SEC EDGARJohn Phillip Ragard, Board member
- 54SEC EDGAREllen O'Connor Vos, Board member
- 55
- 56SEC EDGARStefanie L. Cavanaugh, Board member
- 57SEC EDGARWinfred Parnell, Board member
- 58
- 59SEC EDGARRobert D. Auerbach, Board member
- 60SEC EDGARRuby Sharma, Board member
- 61SEC EDGARNicole Sandford, Board member
- 62SEC EDGARSandra Elaine Brooks, Board member
- 63SEC EDGARNancy G. Cocozza, Board member
- 64SEC EDGARDavid Schreiber, Board member
- 65SEC EDGARVeronica Gh Jordan, Board member
- 66SEC EDGARRobert St Leger Goggin, Board member
- 67SEC EDGAREric Varma, Board member
- 68SEC EDGARJames T. Lafrance, Board member
- 69SEC EDGARBruce A. Huebner, Board member
- 70SEC EDGARCarl Severinghaus, Board member
- 71SEC EDGARPeter S. Roddy, Board member
- 72SEC EDGARWilliam C. Wallen, Board member
- 73SEC EDGARJohn F. Hamilton, Board member
- 74SEC EDGARKenneth J. Conway, Board member
- 75SEC EDGARJames L. Rathmann, Board member
- 76SEC EDGARJudy Bruner, Board member
- 77SEC EDGARMichael J. Callaghan, Board member
- 78SEC EDGARRajen Dalal, Board member
- 79SEC EDGARMinh Hoang Merchant, General counsel
- 80
- 81
- 82
- 83
- 84
- 85SEC EDGARExecutive or director change
- 86SEC EDGARExecutive or director change
- 87SEC EDGARShareholder vote
- 88
- 89SEC EDGAREntered a material agreement
- 90SEC EDGARExecutive or director change
- 91SEC EDGAREntered a material agreement
- 92
- 93SEC EDGARRegulation FD disclosure
- 94
- 95SEC EDGAREntered a material agreement
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114